Emphysema Treatment - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The emphysema treatment market size is expected to grow from USD 5.17 billion in 2025 to USD 5.41 billion in 2026 and is forecast to reach USD 6.84 billion by 2031 at 4.80% CAGR over 2026-2031. This report is segmented by Treatment Type (Medication, Oxygen Therapy, Surgery), Emphysema Phenotype (Centriacinar, Panacinar, Paraseptal, Others), Route of Administration (Inhaled, Oral, Injectable, IV Oxygen), End User (Hospitals, Specialty Pulmonary Centres, Ascs, Homecare, LTC), and Geography (North America, Europe, Asia-Pacific, MEA, South America). Forecasts in Value (USD).

Global Emphysema Treatment Market Trends and Insights

Rising COPD and Emphysema Diagnosis Fuels a Durable Treatment Pipeline

Global COPD prevalence reached 213.4 million cases in 2024, causing 3.7 million deaths annually and ranking among the leading causes of death worldwide. In 2024, only 12% of surveyed residents in China had undergone pulmonary function testing, while India had 55 million people with COPD and accounted for nearly 32% of global COPD deaths amid limited primary-care spirometry access. The WHO projected global COPD cases to rise by 23% by 2050, including a 47.1% increase in incidence among females, while improved diagnosis in China and India could expand treatment demand beyond the forecast period.

Expansion of Minimally Invasive Lung-Volume Reduction Reshapes the Surgical Tier

Bronchoscopic lung-volume reduction expanded procedural capacity in specialist care, supported by a 2025 meta-analysis of nine randomized trials involving 1,352 patients that found endobronchial valves improved FEV1, six-minute walk distance, and quality-of-life scores at 12 months. Pulmonx reported FY2025 revenue of USD 90.5 million, up 8% year over year, with international revenue increasing 23% across more than 25 commercial countries, and had projected 2026 revenue of USD 90 to 92 million with an approximately 75% gross margin. CT-based Chartis and StratX systems became increasingly central to patient eligibility, while the BREATHE-3 trial evaluated the Apreo BREATHE Airway Scaffold in 250 patients across 25 U.S. and European sites and could expand the addressable population by 20%.

High Lifetime Treatment Cost and Unequal Reimbursement Compress Realizable Growth

Biologic therapies for eosinophilic emphysema cost USD 20,000-40,000 annually in the United States. Outside North America, reimbursement often requires prior authorization, defined blood eosinophil levels, and failure of triple inhaled therapy, limiting patient eligibility. In low- and middle-income countries, annual direct and indirect COPD management costs reach USD 420-600 per patient, while home mechanical ventilators cost USD 8,000-15,000 per unit. These cost barriers concentrate the emphysema treatment market in higher-income countries and make emerging-market growth dependent on reimbursement reforms.

Other drivers and restraints analyzed in the detailed report include:

• Novel Anti-Inflammatory and PDE3/4 Therapies Redefine the Pharmacological Tier
• Growth of Home-Based Oxygen and Pulmonary Rehabilitation Creates a Parallel Care Layer
• Limited Spirometry Infrastructure Sustains an Underdiagnosis Ceiling Across Emerging Markets

Segment Analysis

Medication accounted for 61.45% of emphysema treatment market revenue in 2025. Bronchodilators, including LAMA, LABA, fixed-dose combinations, and inhaled corticosteroid add-ons, remained the primary maintenance treatment across disease severity levels. Ensifentrine served symptomatic patients whose disease remained uncontrolled on existing bronchodilators without eosinophil-count qualification. Merck completed its acquisition of Verona Pharma in October 2025, while oxygen therapy remained the second-largest treatment sub-segment following the CMS coverage decision for home mechanical ventilation in June 2025.

Surgery was the fastest-growing treatment type, with the emphysema treatment market size for this segment forecast to grow at a CAGR of 5.22% through 2031. The category included bronchoscopic and open surgical lung-volume reduction, with Zephyr Endobronchial Valve procedures expanding across more than 25 commercial countries. Next-generation devices in pivotal trials may broaden access for patients ineligible for current valve-based approaches. Growth was strongest at high-acuity centers, where medication offered limited benefit for some patients with advanced emphysema, while bronchoscopic lung-volume reduction improved FEV1 and 6-minute walk distance within 12 months.

Centriacinar emphysema accounted for 58.34% of emphysema treatment market revenue in 2025, reflecting its close association with cigarette smoking, the primary exposure history among treated patients. Panacinar emphysema was the fastest-growing phenotype, with a forecast CAGR of 7.56% through 2031, supported by increasing awareness of alpha-1 antitrypsin deficiency and expanded genetic testing. Grifols completed clinical follow-up for its SPARTA Phase III trial, which enrolled 345 participants across 37 sites in 16 countries, and expected topline results by the end of 2026.

The 2025 Canadian Thoracic Society guideline recommended augmentation therapy for eligible patients with a confirmed severe AATD genotype, FEV1 below 80% predicted, and imaging-confirmed emphysema. These criteria supported consistent patient selection and may expand the clinical use of Prolastin-C. Paraseptal emphysema and other phenotypes represented the remaining emphysema treatment market share. Quantitative CT enabled earlier identification than visual radiology alone and may increase their share of treated patients through 2031.

Complete Report Scope:

• By Treatment Type
  • Medication
    • Bronchodilators
    • Steroids
    • Others
  • Oxygen Therapy
  • Surgery
• By Emphysema Phenotype
  • Centriacinar Emphysema
  • Panacinar Emphysema
  • Paraseptal Emphysema
  • Others
• By Route of Administration
  • Inhaled
  • Oral
  • Injectable and Parenteral
  • Intravenous Oxygen and Medical Gas
• By End User
  • Hospitals and Clinics
  • Specialty Pulmonary Centres
  • Ambulatory Surgical Centres
  • Homecare Settings
  • Long-Term Care Facilities
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America accounted for 40.34% of the global emphysema treatment market revenue in 2025, supported by high respiratory healthcare spending, established bronchoscopic lung volume reduction programs, and early biologic launches. The June 2025 CMS decision expanded reimbursed access to home mechanical ventilation for COPD-related chronic respiratory failure. Canada increased augmentation therapy use under updated A1AT guidance, while insurance gaps limited access in Mexico.

Asia-Pacific was the fastest-growing regional segment, with a projected CAGR of 6.45% through 2031. China had 100 million COPD patients as spirometry programs expanded. Japan reimbursed bronchoscopic lung volume reduction from December 2023, and MHLW approved dupilumab as the first biologic for COPD in March 2025. India integrated COPD screening into its National NCD Program, while South Korea expanded reimbursement, and Australia participated in the BREATHE-3 and CONVERT II trials.

Europe was the second-largest regional market and became a two-biologic market for eosinophilic COPD after European Commission approval of mepolizumab in early 2026, alongside dupilumab, approved in July 2024. Germany, the United Kingdom, France, Italy, and Spain generated most regional revenue. The WHO projected a 23% increase in COPD cases in the European Region by 2050 and estimated productivity losses at USD 20.7 billion. Central and Eastern Europe expanded specialist capacity, while biologic reimbursement negotiations lagged Western Europe by 18-24 months. The Middle East, Africa, and South America remained the smallest regions, although GCC countries and Brazil expanded private respiratory endoscopy capacity and access to branded bronchodilators.

List of Companies Covered in this Report:

• AstraZeneca
• Boehringer Ingelheim
• Broncus Medical, Inc.
• Chiesi Farmaceutici
• Cipla
• Gala Therapeutics, Inc.
• Grifols
• GlaxoSmithKline
• Hikma Pharmaceuticals
• Koninklijke Philips
• Novartis
• Nuvaira, Inc.
• Olympus
• Orion
• Pfizer
• Pulmatrix, Inc.
• Pulmonx Corporation
• Regeneron Pharmaceuticals
• Resmed
• Sanofi
• Sun Pharmaceuticals Industries
• Teva Pharmaceutical Industries
• Verona Pharma plc
• Viatris

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support